数据简报-美国制药企业纷纷转向中国寻求许可协议

路透中文

Sep 28

路透9月28日 - 默克公司（MRK.N ）周一同意向中国生物技术公司 (link) SciBrunch Therapeutics支付4亿美元预付款，以获得一种实验性抗癌药的全球权益，成为最新一家获得中国研发药物授权的美国制药商。

中国生物技术公司通常会保留国内权益 (link)，并将药物授权给海外企业，以此换取预付款、里程碑付款以及专利使用费。

以下列举了部分重大交易：

日期	美国公司	中国公司	交易类型	资产/项目	预付款金额	潜在价值
2026年9月	默克 MRK.N	SciBrunch Therapeutics	许可 (link)	SPR2015，实验性抗癌药物	4亿美元	最高21.3亿美元
2026年5月	辉瑞 PFE.N	Innovent Biologics 1801.HK	许可 (link)	12个早期阶段的肿瘤学项目	6.5亿美元	最高105亿美元
2026年5月	百时美施贵宝 BMY.N	江苏恒瑞医药 600276.SS	许可 (link)	13个处于早期阶段的肿瘤学、血液学和免疫学项目	6亿美元	最高152亿美元
2026年2月	礼来 LLY.N	Innovent Biologics	许可 (link)	实验性癌症和免疫学药物	3.5亿美元	最高88.5亿美元
2026年1月	艾伯维 ABBV.N	RemeGen 688331.SS	许可 (link)	RC148，实验性抗癌药物	6.5亿美元	最高56亿美元
2025年6月	Regeneron Pharmaceuticals REGN.O	汉索制药	许可 (link)	HS-20094/奥拉托雷肽，GLP-1/GIP类减肥药	8,000万美元	最高20.1亿美元
2025年5月	辉瑞	3SBio 1530.HK	许可 (link)	SSGJ-707，实验性抗癌药物	12.5亿美元	最高60.5亿美元，不包括辉瑞1亿美元的股权投资
2024年12月	默克	Hansoh Pharma 3692.HK	许可 (link)	HS-10535，口服减肥药	1.12亿美元	最高20亿美元
2024年11月	默克	LaNova Medicines	许可 (link)	LM-299，实验性抗癌药物	5.88亿美元	最高33亿美元
2024年6月	艾伯维	FutureGen生物制药	许可 (link)	FG-M701，实验性炎症性肠病药物	1.5亿美元	最高17.1亿美元
2023年12月	百时美施贵宝	四川博金制药 688506.SS /SystImmune	许可 (link)	BL-B01D1，实验性抗体抗癌药物	8亿美元	最高84亿美元
2022年12月	Summit Therapeutics SMMT.O	Akeso 9926.HK	许可 (link)	Ivonescimab，实验性癌症疗法	5亿美元	最高50亿美元

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2670555622"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2670555622\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2670555622?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-28 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2670555622","market":"hk","top_or_hot":-1,"title":"数据简报-美国制药企业纷纷转向中国寻求许可协议","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>数据简报-美国制药企业纷纷转向中国寻求许可协议</title></head><body>路透9月28日 - 默克公司（MRK.N ） 周一同意向中国<a href=\"https://laohu8.com/S/000504\">生物</a>技术公司 (link) SciBrunch <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>支付4亿美元预付款，以获得一种实验性抗癌药的全球权益，成为最新一家获得中国研发药物授权的美国制药商。中国生物技术公司通常会保留国内权益 (link)，并将药物授权给海外企业，以此换取预付款、里程碑付款以及专利使用费。以下列举了部分重大交易：<table><tbody><tr><td>日期</td><td>美国公司</td><td>中国公司</td><td>交易类型</td><td>资产/项目</td><td>预付款金额</td><td>潜在价值</td></tr><tr><td>2026年9月</td><td>默克 MRK.N </td><td>SciBrunch Therapeutics</td><td>许可 (link)</td><td>SPR2015，实验性抗癌药物</td><td>4亿美元</td><td>最高21.3亿美元</td></tr><tr><td>2026年5月</td><td><a href=\"https://laohu8.com/S/PFE\">辉瑞</a> PFE.N </td><td><a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> 1801.HK </td><td>许可 (link)</td><td>12个早期阶段的肿瘤学项目</td><td>6.5亿美元</td><td>最高105亿美元</td></tr><tr><td>2026年5月</td><td>百时美<a href=\"https://laohu8.com/S/BMY\">施贵宝</a> BMY.N</td><td>江苏<a href=\"https://laohu8.com/S/600276\">恒瑞医药</a> 600276.SS </td><td>许可 (link)</td><td>13个处于早期阶段的肿瘤学、血液学和免疫学项目</td><td>6亿美元</td><td>最高152亿美元</td></tr><tr><td>2026年2月</td><td><a href=\"https://laohu8.com/S/LLY\">礼来</a> LLY.N</td><td><a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics</a></td><td>许可 (link)</td><td>实验性癌症和免疫学药物</td><td>3.5亿美元</td><td>最高88.5亿美元 </td></tr><tr><td>2026年1月 </td><td>艾伯维 ABBV.N </td><td>RemeGen 688331.SS </td><td>许可 (link)</td><td>RC148，实验性抗癌药物</td><td>6.5亿美元</td><td>最高56亿美元 </td></tr><tr><td>2025年6月</td><td>Regeneron Pharmaceuticals REGN.O </td><td>汉索制药</td><td>许可 (link)</td><td>HS-20094/奥拉托雷肽，GLP-1/GIP类减肥药</td><td>8,000万美元</td><td>最高20.1亿美元</td></tr><tr><td>2025年5月</td><td>辉瑞</td><td>3SBio 1530.HK </td><td>许可 (link)</td><td>SSGJ-707，实验性抗癌药物 </td><td>12.5亿美元</td><td>最高60.5亿美元，不包括辉瑞1亿美元的股权投资</td></tr><tr><td>2024年12月</td><td>默克</td><td>Hansoh Pharma 3692.HK </td><td>许可 (link)</td><td>HS-10535，口服减肥药</td><td>1.12亿美元</td><td>最高20亿美元</td></tr><tr><td>2024年11月</td><td>默克 </td><td>LaNova Medicines</td><td>许可 (link)</td><td>LM-299，实验性抗癌药物</td><td>5.88亿美元</td><td>最高33亿美元</td></tr><tr><td>2024年6月</td><td>艾伯维</td><td>FutureGen生物制药</td><td>许可 (link)</td><td>FG-M701，实验性炎症性肠病药物</td><td>1.5亿美元</td><td>最高17.1亿美元</td></tr><tr><td>2023年12月</td><td>百时美施贵宝</td><td>四川博金制药 688506.SS /SystImmune</td><td>许可 (link)</td><td>BL-B01D1，实验性抗体抗癌药物</td><td>8亿美元</td><td>最高84亿美元</td></tr><tr><td>2022年12月</td><td><a href=\"https://laohu8.com/S/SMMT\">Summit</a> Therapeutics SMMT.O </td><td>Akeso 9926.HK </td><td>许可 (link)</td><td>Ivonescimab，实验性癌症疗法</td><td>5亿美元</td><td>最高50亿美元 </td></tr></tbody></table></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>数据简报-美国制药企业纷纷转向中国寻求许可协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n数据简报-美国制药企业纷纷转向中国寻求许可协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n路透中文 \n2026-09-28 22:32\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>数据简报-美国制药企业纷纷转向中国寻求许可协议</title></head><body>路透9月28日 - 默克公司（MRK.N ） 周一同意向中国<a href=\"https://laohu8.com/S/000504\">生物</a>技术公司 (link) SciBrunch <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>支付4亿美元预付款，以获得一种实验性抗癌药的全球权益，成为最新一家获得中国研发药物授权的美国制药商。中国生物技术公司通常会保留国内权益 (link)，并将药物授权给海外企业，以此换取预付款、里程碑付款以及专利使用费。以下列举了部分重大交易：<table><tbody><tr><td>日期</td><td>美国公司</td><td>中国公司</td><td>交易类型</td><td>资产/项目</td><td>预付款金额</td><td>潜在价值</td></tr><tr><td>2026年9月</td><td>默克 MRK.N </td><td>SciBrunch Therapeutics</td><td>许可 (link)</td><td>SPR2015，实验性抗癌药物</td><td>4亿美元</td><td>最高21.3亿美元</td></tr><tr><td>2026年5月</td><td><a href=\"https://laohu8.com/S/PFE\">辉瑞</a> PFE.N </td><td><a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> 1801.HK </td><td>许可 (link)</td><td>12个早期阶段的肿瘤学项目</td><td>6.5亿美元</td><td>最高105亿美元</td></tr><tr><td>2026年5月</td><td>百时美<a href=\"https://laohu8.com/S/BMY\">施贵宝</a> BMY.N</td><td>江苏<a href=\"https://laohu8.com/S/600276\">恒瑞医药</a> 600276.SS </td><td>许可 (link)</td><td>13个处于早期阶段的肿瘤学、血液学和免疫学项目</td><td>6亿美元</td><td>最高152亿美元</td></tr><tr><td>2026年2月</td><td><a href=\"https://laohu8.com/S/LLY\">礼来</a> LLY.N</td><td><a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics</a></td><td>许可 (link)</td><td>实验性癌症和免疫学药物</td><td>3.5亿美元</td><td>最高88.5亿美元 </td></tr><tr><td>2026年1月 </td><td>艾伯维 ABBV.N </td><td>RemeGen 688331.SS </td><td>许可 (link)</td><td>RC148，实验性抗癌药物</td><td>6.5亿美元</td><td>最高56亿美元 </td></tr><tr><td>2025年6月</td><td>Regeneron Pharmaceuticals REGN.O </td><td>汉索制药</td><td>许可 (link)</td><td>HS-20094/奥拉托雷肽，GLP-1/GIP类减肥药</td><td>8,000万美元</td><td>最高20.1亿美元</td></tr><tr><td>2025年5月</td><td>辉瑞</td><td>3SBio 1530.HK </td><td>许可 (link)</td><td>SSGJ-707，实验性抗癌药物 </td><td>12.5亿美元</td><td>最高60.5亿美元，不包括辉瑞1亿美元的股权投资</td></tr><tr><td>2024年12月</td><td>默克</td><td>Hansoh Pharma 3692.HK </td><td>许可 (link)</td><td>HS-10535，口服减肥药</td><td>1.12亿美元</td><td>最高20亿美元</td></tr><tr><td>2024年11月</td><td>默克 </td><td>LaNova Medicines</td><td>许可 (link)</td><td>LM-299，实验性抗癌药物</td><td>5.88亿美元</td><td>最高33亿美元</td></tr><tr><td>2024年6月</td><td>艾伯维</td><td>FutureGen生物制药</td><td>许可 (link)</td><td>FG-M701，实验性炎症性肠病药物</td><td>1.5亿美元</td><td>最高17.1亿美元</td></tr><tr><td>2023年12月</td><td>百时美施贵宝</td><td>四川博金制药 688506.SS /SystImmune</td><td>许可 (link)</td><td>BL-B01D1，实验性抗体抗癌药物</td><td>8亿美元</td><td>最高84亿美元</td></tr><tr><td>2022年12月</td><td><a href=\"https://laohu8.com/S/SMMT\">Summit</a> Therapeutics SMMT.O </td><td>Akeso 9926.HK </td><td>许可 (link)</td><td>Ivonescimab，实验性癌症疗法</td><td>5亿美元</td><td>最高50亿美元 </td></tr></tbody></table></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF631.EUR","symbol_name":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nL4T45K134:1","article_id":"2670555622","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2670555622","pubTimestamp":1790605948,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"数据简报-美国制药企业纷纷转向中国寻求许可协议路透9月28日-默克公司周一同意向中国生物技术公司 SciBrunch Therapeutics支付4亿美元预付款，以获得一种实验性抗癌药的全球权益，成为最新一家获得中国研发药物授权的美国制药商。中国生物技术公司通常会保留国内权益 ，并将药物授权给海外企业，以此换取预付款、里程碑付款以及专利使用费。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","688331":"荣昌生物","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","01801":"信达生物","BK0239":"医药制造","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4516":"特朗普概念","LU2596442595.SGD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (SGDHDG) INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999001176.USD":"United Global Healthcare Acc USD","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","IE000F7OJYX1.SGD":"RQI GLOBAL \"I\" (SGDHDG) INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","IE0000B7K699.USD":"RQI GLOBAL \"I\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE000BZT7R73.USD":"RQI GLOBAL \"I\" (USD) ACC","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","IE000MB6IJN5.SGD":"RQI GLOBAL \"I\" (SGD) ACC","LU0395794307.EUR":"JPM GLOBAL INCOME (DIV) \"A\" (EUR) INC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","BK4559":"巴菲特持仓","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","BMED":"iShares Health Innovation Active ETF","BK4550":"红杉资本持仓","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","AGNG":"Global X Aging Population ETF","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","TRUH":"VanEck Healthcare TruSector ETF","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","IE000WAW04H5.SGD":"RQI GLOBAL \"I\" (SGD) INC A","BK1574":"生物医药B类股","WDNA":"WisdomTree BioRevolution Fund","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","IE000SO60NU8.SGD":"RQI GLOBAL \"I\" (SGDHDG) ACC A","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU0472753341.HKD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (HKD) ACC","ILDR":"First Trust Innovation Leaders ETF","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","09995":"荣昌生物","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","ELIL":"2倍做多LLY ETF-Direxion","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","ELIS":"1倍做空LLY ETF-Direxion","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU1979441026.SGD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"A\" (SGDHDG) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LLYX":"2倍做多LLY ETF-Defiance","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0861579265.USD":"联博低波幅策略股票基金A","LLYZ":"2倍做空LLY ETF-Defiance","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0183":"MSCI概念","BK1589":"北水核心资产","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","BK1191":"制药","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","LU0237698245.USD":"富达环球地产基金A","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","BK0060":"抗癌","BK4532":"文艺复兴科技持仓","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","BK4534":"瑞士信贷持仓","FHLC":"Fidelity MSCI Health Care Index","LU0353189763.USD":"ALLSPRING US ALL CAP GROWTH FUND \"I\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK0188":"融资融券","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LLY":"礼来","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS CHINA INNOVATION \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","BK0196":"行业龙头","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","BK1583":"高瓴概念","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU0149534421.HKD":"SCHRODER ISF HONG KONG EQ \"A\" ACC","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK0012":"证金概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","LU0079474960.USD":"联博美国增长基金A","IHE":"iShares U.S. Pharmaceuticals ETF","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","BK4566":"资本集团","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","SG9999015978.USD":"利安颠覆性创新基金A","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","BK4568":"美国抗疫概念","LU0133085943.USD":"T ROWE PRICE US BLUE CHIP EQUITY \"A\" ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0174119429.USD":"T ROWE PRICE US LARGE CAP GROWTH EQUITY \"A\" ACC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","REGN":"再生元制药公司","CURE":"Direxion Daily Healthcare Bull 3X ETF","BK4007":"制药","LU2462591350.SGD":"T ROWE PRICE US LARGE CAP GROWTH EQUITY \"AN\" (SGDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","XLV":"健康照护类股ETF-SPDR","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1032466523.USD":"高盛全球多资产收益组合Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU2237443465.HKD":"abrdn SICAV I - GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU1720050803.USD":"安联全方位中国股票基金","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","BK4139":"生物科技","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0726765562.USD":"JPM GLOBAL INCOME \"A\" (USD HEDGED) INC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2347655073.USD":"JPM GLOBAL INCOME \"A\" (USDHDG) INC A","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","BK4592":"伊斯兰概念","PFE":"辉瑞","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BBH":"VanEck Biotech ETF","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","01530":"三生制药","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU2087625088.SGD":"ALLSPRING US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","MEDI":"HARBOR HEALTH CARE ETF","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","03692":"翰森制药","MEDX":"HORIZON KINETICS MEDICAL ETF","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","HRTS":"Tema Heart & Health ETF","IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","PPH":"VanEck Pharmaceutical ETF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0502904849.HKD":"FIDELITY FUNDS CHINA INNOVATION \"A\" (HKD) ACC","BK4588":"碎股","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","BK1161":"生物科技","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","BK4599":"减肥药","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","GDOC":"Goldman Sachs Future Health Care Equity ETF","SG9999002232.USD":"Allianz Global High Payout USD","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","IBB":"生物科技指数ETF-iShares Nasdaq","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","TMED":"T. Rowe Price Health Care ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","SMMT":"Summit Therapeutics PLC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","ABBV":"艾伯维公司","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","IE0001KFT4U8.USD":"FTGF CLEARBRIDGE GLOBAL GROWTH LEADERS \"A\" (USD) INC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD) INC AV","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","PJP":"INVESCO PHARMACEUTICALS ETF","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK0028":"国家队","LLII":"REX LLY Growth & Income ETF","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","BK4581":"高盛持仓","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","MRK":"默沙东","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0607220059.USD":"SCHRODER ISF HONG KONG EQUITY \"A\" (USD) ACC","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0354030511.USD":"ALLSPRING U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","BK1593":"医美概念股","01276":"恒瑞医药","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1831875114.USD":"SCHRODER ISF ALL CHINA EQUITY \"A\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","MHIP":"Milliman Healthcare Inflation Plus ETF","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","OZEM":"Roundhill GLP-1 & Weight Loss ETF","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) INC (M)","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","IXJ":"全球医疗业ETF-iShares","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","09926":"康方生物","LU2063271972.USD":"富兰克林创新领域基金","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","VHT":"Vanguard Health Care ETF","LU2237443895.HKD":"abrdn SICAV I - GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","BMY":"施贵宝","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","CANC":"TEMA ONCOLOGY ETF","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","PAWZ":"ProShares Pet Care ETF","LU0385154629.USD":"贝莱德营养科学基金A2","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","IYH":"iShares U.S. Healthcare ETF","RXL":"ProShares Ultra Health Care","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC"},"translate_title":"Data Brief - US pharmaceutical companies are turning to China for licensing agreements","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.87,"688331":1.86,"LLY":1.88,"THNR":0.6,"MEDI":0.6,"PAWZ":0.6,"HRTS":0.6,"RXL":0.6,"FTXH":0.6,"TMED":0.6,"ELIL":0.6,"MRK":1.95,"CANC":0.6,"REGN":1.86,"01276":1.87,"PPH":0.6,"BMED":0.6,"03692":1.86,"KURE":0.6,"MEDX":0.6,"LLYX":0.6,"PFE":1.91,"IBBQ":0.6,"01801":1.88,"AGNG":0.6,"PJP":0.6,"IHE":0.6,"SMMT":1.86,"TRUH":0.6,"OZEM":0.6,"XLV":0.6,"IBB":0.6,"09995":1.86,"BMY":1.87,"WDNA":0.6,"FHLC":0.6,"BBH":0.6,"LLYZ":0.6,"ELIS":0.6,"VHT":0.6,"TBXU":0.6,"IXJ":0.6,"IYH":0.6,"GLAM":0.6,"GDOC":0.6,"ABBV":1.88,"JDOC":0.6,"LLII":0.6,"MHIP":0.6,"01530":1.86,"ILDR":0.6,"09926":1.86,"CURE":0.6},"content_text":"数据简报-美国制药企业纷纷转向中国寻求许可协议路透9月28日 - 默克公司（MRK.N ） 周一同意向中国生物技术公司 (link) SciBrunch Therapeutics支付4亿美元预付款，以获得一种实验性抗癌药的全球权益，成为最新一家获得中国研发药物授权的美国制药商。中国生物技术公司通常会保留国内权益 (link)，并将药物授权给海外企业，以此换取预付款、里程碑付款以及专利使用费。以下列举了部分重大交易：日期美国公司中国公司交易类型资产/项目预付款金额潜在价值2026年9月默克 MRK.N SciBrunch Therapeutics许可 (link)SPR2015，实验性抗癌药物4亿美元最高21.3亿美元2026年5月辉瑞 PFE.N Innovent Biologics 1801.HK 许可 (link)12个早期阶段的肿瘤学项目6.5亿美元最高105亿美元2026年5月百时美施贵宝 BMY.N江苏恒瑞医药 600276.SS 许可 (link)13个处于早期阶段的肿瘤学、血液学和免疫学项目6亿美元最高152亿美元2026年2月礼来 LLY.NInnovent Biologics许可 (link)实验性癌症和免疫学药物3.5亿美元最高88.5亿美元 2026年1月 艾伯维 ABBV.N RemeGen 688331.SS 许可 (link)RC148，实验性抗癌药物6.5亿美元最高56亿美元 2025年6月Regeneron Pharmaceuticals REGN.O 汉索制药许可 (link)HS-20094/奥拉托雷肽，GLP-1/GIP类减肥药8,000万美元最高20.1亿美元2025年5月辉瑞3SBio 1530.HK 许可 (link)SSGJ-707，实验性抗癌药物 12.5亿美元最高60.5亿美元，不包括辉瑞1亿美元的股权投资2024年12月默克Hansoh Pharma 3692.HK 许可 (link)HS-10535，口服减肥药1.12亿美元最高20亿美元2024年11月默克 LaNova Medicines许可 (link)LM-299，实验性抗癌药物5.88亿美元最高33亿美元2024年6月艾伯维FutureGen生物制药许可 (link)FG-M701，实验性炎症性肠病药物1.5亿美元最高17.1亿美元2023年12月百时美施贵宝四川博金制药 688506.SS /SystImmune许可 (link)BL-B01D1，实验性抗体抗癌药物8亿美元最高84亿美元2022年12月Summit Therapeutics SMMT.O Akeso 9926.HK 许可 (link)Ivonescimab，实验性癌症疗法5亿美元最高50亿美元","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}